Sleep Quality & Psoriatic Arthritis
For people living with psoriatic arthritis (PsA), the comfort of a good night's sleep may feel out of reach for many.
Read more →What's hot
View all perspectives
What's Hot
Ultrasound in PsA
Dr. Arthur Kavanaugh discusses abstract 2206 presented at ACR22 in Philadelphia. Abstract 2206: Understanding Inter-rater Variability in Scoring of Entheseal Lesions: Results from the Diagnostic Ultrasound Enthesitis Tool (DUET) Study
Watch video →
Tapering TNFi in nonradiographic AxSpA
Dr. Peter Nash at ACR22 Convergence in Philadelphia, PA.
Watch video →
Sunday (Day 2): ACR 22 Daily Recap
ACR 2022 Daily Recap for Sunday, November 13th. Panelists: Drs. Robert Chao, Antoni Chan, Bella Mehta, Janet Pope, Yuz Yusof, Cassy Sims, Akhil Sood, Sheila Reyes and Jack Cush.
Watch video →
Spondyloarthritis: Novel Therapies, Diagnostic Dilemmas and Depression
Dr. Lianne Gensler discusses the following abstracts presented at ACR22 Convergence. Abstracts 1597, 1598, 1599 (treatment) and 1613, 1609 and 1614 (diagnosis and outcomes)
Watch video →
Deucravacitinib in PsA
Dr. Arthur Kavanaugh discusses abstract 1598 at ACR22 Convergence in Philadelphia. Abstract 1598: Safety and Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Psoriatic Arthritis: 52-Week Results from a Randomized Phase 2 Trial
Watch video →
Sarilumab in Polymyalgia Rheumatica: Results from SAPHYR Trial
Dr. Michael Putman interviews Dr. Robert Speira about abstract 1676 presented at the ACR22 Convergence meeting in Philadelphia, PA. Abstract 1676: Sarilumab in Patients with Relapsing Polymyalgia Rheumatica: A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Trial (SAPHYR)
Watch video →
PET CT Imaging to Define Risk of Progression from PSO to PsA
Dr. Peter Nash discusses Abstract 1018 at ACR22 Convergence.
Watch video →
ACR22 Daily Recap: Saturday Recap
Panelists: Drs. Jack Cush, Michael Putman, Eric Dein, Patricia Harkins and Rachel Tate.
Watch video →
Dr. Antoni Chan synovialjoints
3 years 1 month ago
Increasing fracture incidence rates for both AS and comparator groups. Increased in the TNFi era (2004-2021) relative to the pre-TNFi era (2000-2003). The ratio (AS/comparators) appear stable over the past 2 decades
Merjanah S Abs1911 https://t.co/lLtW4eh0nm #ACR22 @RheumNow https://t.co/1Nr6ru1vPv
Dr. John Cush RheumNow
3 years 1 month ago
Tune in to Twitter, Facebook or LinkedIn daily at 5pm ET. Catch our daily recap LIVE! #ACR22 https://t.co/fgwqIjuXJ4
sheila RHEUMarampa
3 years 1 month ago
Lifestyle modifications can affect tx response with TNFi in axSpA!
Accdg to this study fr Prof GJones, ✳️Smokers, overwt & obese pts are ⬇️ likely to achieve treatment response to TNFi vs. nonsmokers & normal wt pts
Smoking cessation, wt mgt is key!
#ACR22 @RheumNow ABST#1510 https://t.co/PBFcj6zKVD
Richard Conway RichardPAConway
3 years 1 month ago
De Craemer et al. Local vs Central reading of images. Rheumatologists overcall sacroiliitis on both plain films and MRI in ?AxSpA . ? some of this out of a desire to try something to help someone who is suffering @RheumNow #ACR22 Abstr#1255 https://t.co/j89E0sUPmN https://t.co/Ez5ldSSQJl
Richard Conway RichardPAConway
3 years 1 month ago
Ramahi @sclerodermaUM et al Risk factors for ILD decline in SSc. Anti-Topoisomerase I only identified factor in multivariable model. @RheumNow #ACR22 Abstr#1524 https://t.co/lc2BPjgqiC https://t.co/qx3M6dfd3w
Dr. Antoni Chan synovialjoints
3 years 1 month ago
Plenary:
Tyrosine kinase 2 (TYK2)
◦ Mediates signaling of Type I IFNs, IL-23, and IL-12
◦ Key cytokines involved in lupus pathogenesis
◦ Deucravacitinib oral TYK2 inhibitor
◦ Phase 2 RCT in SLE showed efficacy
Pike M Abs1117 https://t.co/eJhNsM02Vl #ACR22 @RheumNow https://t.co/C6JQqR1DLj
Richard Conway RichardPAConway
3 years 1 month ago
Doyen et al. FIND-RA study. RA for >1<10 years. RA-ILD 12%, air trapping 58%, rheumatoid nodules 11%. @RheumNow #ACR22 Abstr#1393 https://t.co/Sy1qwZJq5E https://t.co/ww8HgHT32E
Dr. Rachel Tate uptoTate
3 years 1 month ago
There is an association between the severity of skin and joint or axial disease, both at baseline and longitudinally, in pts presenting w/in 12 months of diagnosis of PsA. Abs 1511 #ACR22 @RheumNow https://t.co/PcVn6dITqU https://t.co/qxn3LBOW8d
Richard Conway RichardPAConway
3 years 1 month ago
Sanchez Martin et al. Assessing effect tocilizumab by PET in GCA. Vascular involvement not generally fully controlled by tocilizumab. Not sure how PET was scored here. @RheumNow #ACR22 Abstr#1257 https://t.co/cGEoScnPb3 https://t.co/W0yYMPMjni
Richard Conway RichardPAConway
3 years 1 month ago
Yen et al. Taiwanese study of risk of MACE in SSc. No difference in MACE IRR 1.15 (95%CI 0.87–1.52) or stroke IRR 0.89 (95%CI 0.61-1.29), increase in MI IRR 1.76 (95%CI 1.08-2.86) @RheumNow #ACR22 Abstr#1191 https://t.co/3BiTLafGmk https://t.co/IManEvAh47
Dr. Rachel Tate uptoTate
3 years 1 month ago
HZ risk after each (1 of 3) BNT162b2 mRNA vaccination doses was not increased in PsA and AS patients compared to a similar time period two years prior . The risk of HZ increased with age. Abs 1489 #ACR22 @RheumNow https://t.co/YmcqDNoxya
David Liew drdavidliew
3 years 1 month ago
I find this incredibly encouraging
SAPHYR subanalysis:
refractory PMR
sarilumab (w 14w PNL taper) vs placebo (w 52w taper)
?no Sx
Benefit kicks on after PNL taper stops, out to 52w
Reality in practice: bit more PNL prob gives excellent Sx outcomes
ABST1543 #ACR22 @RheumNow https://t.co/kGBZyULZeU
Robert B Chao, MD doctorRBC
3 years 1 month ago
Even a 6 month delay in PsA diagnosis can lead to worse PROs on quality of life!
Likelihood of depression increased
Pts with PsA dx in <6 months reported better outcomes
Abs#1507 @RheumNow #ACR22 https://t.co/igCiH22CWi
Poster Hall